Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Form:LiquidSee storage information,
Knockout validation:Next Generation Sequencing,Western blot,
Mutation description:Knockout achieved by CRISPR/Cas9 X = 2 bp deletion Frameshift: 100%,
Disease:Adenocarcinoma
Product details:
We will provide viable cells that proliferate on revival.
Western blot data indicates that the CRISPR gene edit may have resulted in a truncation of the protein of interest. Please see data images.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-EGR1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Western blot, Shipped at conditions-Dry Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions--196°C, -80°C, Appropriate long-term storage conditions--196°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Egr1 also known as early growth response protein 1 is a zinc-finger transcription factor with a molecular weight of approximately 60 kDa. The Egr1 protein plays a significant role in gene expression regulation by binding to specific DNA sequences. This target is highly expressed in a variety of tissues including the brain heart and kidneys. In these tissues Egr1 regulates several cellular processes by activating or repressing target genes. Also Egr1 has monoclonal antibodies available for research purposes providing tools for detailed study in specific cellular contexts.
Biological function summary
Egr1 acts as an immediate-early response gene. It gets rapidly upregulated in response to growth factors stress signals and other extracellular stimuli. As part of the cellular signaling networks Egr1 interacts with other transcription factors to control the expression of genes involved in cell differentiation proliferation and apoptosis. It does not typically form part of a protein complex but may work in concert with other signaling molecules to influence diverse cellular pathways and maintain cellular homeostasis.
Pathways
Egr1 is involved in the MAPK/ERK and PI3K/AKT signaling pathways both key to regulating cellular growth and survival. It functions as a bridging factor that links extracellular signals to transcriptional changes within the nucleus. In the MAPK/ERK pathway Egr1 works alongside proteins like Ras and MEK to promote early gene transcription in response to mitogenic signals. In the PI3K/AKT pathway Egr1 can influence downstream targets reinforcing the pathway's mechanisms in determining cell fate.
Egr1 is linked to cancer and cardiovascular diseases. Abnormal Egr1 expression and activity have been observed in various cancers where it can act as an oncogene or tumor suppressor depending on the context. Abnormal interactions with proteins such as p53 may contribute to tumorigenesis. In cardiovascular diseases Egr1 influences pathological states by regulating genes associated with inflammation and vascular remodeling. The protein's dysregulation plays a part in atherosclerosis connecting with inflammatory cytokines to promote disease progression.
